Trial Profile

A Phase 2, Randomized, Double Blind, Controlled Study to Evaluate the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ivacaftor (Primary) ; Ivacaftor/tezacaftor (Primary) ; VX 152 (Primary)
Indications Cystic fibrosis
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Vertex Pharmaceuticals

Most Recent Events

21 Feb 2018 Status changed from recruiting to completed.
18 Jul 2017 Results published in the Vertex Pharmaceuticals media release.
08 Jan 2017 According to a Vertex Pharmaceuticals media release, the first data from this trial are expected in the second half of 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com